Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCRJ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,168
Award facts
- Contract value 100% obligated
- $33,168.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $33,168.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award was made on November 17, 2025, with an ultimate completion date of December 9, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499,999,999 single-award contract designated SPE2DR that was awarded on November 13, 2025.
The PPV-G GEN V program represents a critical component of the Department of Defense's pharmaceutical supply chain infrastructure, authorized to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's selection as a regional prime vendor contractor reflects its established performance in supplying specialized pharmaceutical products, including immunosuppressants and biologic agents such as Stelara, to federal military medical operations. The contract positions the company to serve as a key supplier for recurring medical supply needs across the global Defense medical system through the 30-month base period and three optional 30-month renewal periods extending through December 31, 2036.
Quick answers
Who was awarded contract SPE2DR26FCRJ5?
SPE2DR26FCRJ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FCRJ5 worth?
The government has obligated $33,168 on SPE2DR26FCRJ5.
Is contract SPE2DR26FCRJ5 an order under another contract?
Yes. SPE2DR26FCRJ5 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRJ5 competed?
The extent of competition for SPE2DR26FCRJ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award